title: cDNA cloning and sequencing of a novel monoclonal antibody to carcinoembryonic antigen and construction of a mouse/human chimeric antibody.
abstract: BACKGROUND
  Mouse monoclonal antibody F33-104 recognizes an epitope which is present on the carcinoembryonic antigen (CEA) molecule but not on the other CEA family member proteins, and which seems to be of potential value for immunotherapy of CEA-expressing cancers. However, an inherent problem in its in vivo application is the human anti-mouse antibody response.
  
  
  METHODS
  To reduce its immunogenicity in humans, we cloned and sequenced the V region genes of heavy and light chains of F33-104 using the reverse transcription-polymerase chain reaction method, and then constructed a mouse/human chimeric antibody, designated Ch F33-104, by fusing the F33-104 VH and V kappa genes to human C gamma 1 and C kappa genes, respectively. The resulting Ch F33-104 was expressed in non-Ig-producing myeloma cells and characterized for its CEA binding specificity and the tumor cell killing activity.
  
  
  RESULTS
  Ch F33-104 specifically bound to CEA-expressing tumor cells and revealed a potent antibody-dependent cell-mediated cytotoxicity with human lymphokine-activated killer cells as effectors against the CEA-expressing tumor cells.
  
  
  CONCLUSIONS
  This mouse/human chimeric antibody could therefore be a candidate for cancer immunotherapy of CEA-positive cancers.
authors.affiliation: Department of Biochemistry, Fukuoka University School of Medicine, 7-45-1 Nanakuma, Jonan-ku, Fukuoka, 814-0180, Japan.
authors.forename: Hirotomo
authors.initials: H
authors.lastname: Shibaguchi
authors.forename: Fumiko
authors.initials: F
authors.lastname: Arakawa
authors.forename: Takayuki
authors.initials: T
authors.lastname: Imakiire
authors.forename: Motomu
authors.initials: M
authors.lastname: Kuroki
authors.forename: Masahide
authors.initials: M
authors.lastname: Kuroki
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D000911:Antibodies, Monoclonal / Q000096:biosynthesis / Q000235:genetics* / Q000276:immunology*; D000920:Antibody-Dependent Cell Cytotoxicity / Q000276:immunology; D001483:Base Sequence; D002272:Carcinoembryonic Antigen / Q000276:immunology*; D045744:Cell Line, Tumor; D018076:DNA, Complementary / Q000235:genetics / Q000276:immunology; D005434:Flow Cytometry; D005784:Gene Amplification; D005822:Genetic Vectors / Q000235:genetics; D006801:Humans; D006825:Hybridomas; D007143:Immunoglobulin Heavy Chains / Q000235:genetics / Q000276:immunology; D007147:Immunoglobulin Light Chains / Q000235:genetics / Q000276:immunology; D007135:Immunoglobulin Variable Region / Q000235:genetics / Q000276:immunology; D051379:Mice; D008969:Molecular Sequence Data; D011993:Recombinant Fusion Proteins / Q000235:genetics* / Q000276:immunology*; D050378:T-Lymphocytes, Regulatory / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D002272:Carcinoembryonic Antigen; D018076:DNA, Complementary; D007143:Immunoglobulin Heavy Chains; D007147:Immunoglobulin Light Chains; D007135:Immunoglobulin Variable Region; D011993:Recombinant Fusion Proteins